Skip to main content
Regeneron10-Q: Compliance burden

Regeneron Agrees to Most-Favored-Nation Medicaid Pricing and Direct Purchasing with U.S. Government in April 2026

Source: Autobound Signal API · 93 signals tracked for Regeneron · updated

Get Regeneron's live signals in Claude or ChatGPT, or by API

AskWhat changed at Regeneron this week? Use Autobound signals for regeneron.com.

What happened

Regeneron entered into agreements with the U.S. government to benchmark U.S.-wholly owned products sold to Medicaid against foreign developed countries and participate in TrumpRx.gov.

Source

SEC EDGARApr 29, 2026

Quarterly report (Form 10-Q)

Regeneron 10-Q for Quarter ended Mar 31, 2026

Filing excerpt

In April 2026, we announced agreements with the U.S. government (the "U.S. Government Agreements") pursuant to which we have agreed, among other matters, to provide certain of our products that we wholly own in the United States to the Medicaid program at or below prices benchmarked against a defined group of other developed countries ("Most-Favored-Nation Pricing"). We have also agreed to price certain future medicines in the United States at or below Most-Favored-Nation Pricing; to participate in a direct purchasing platform, TrumpRx.gov, that will allow eligible patients to purchase Praluent directly; and to provide our recently FDA-approved gene therapy Otarmeni™ for free in the United States.

sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htmRead the full source

Other signals in this filing (4)

Extracted by Autobound

From the Signal API record
Signal
10-Q: Compliance burden

What this signalsFilings often name leadership changes, deals and spending plans.

Period
Quarter ended Mar 31, 2026
Fiscal year end
03/31
Filed
Apr 29, 2026

More 10-Q signals at other companies

The full record

From the Signal API record

Details

CIK
872589
Accession number
0000872589-26-000016
Timeframe
Multi year
Quarter
Q1
Filing year
2026
Period end date
Mar 31, 2026
Why it matters
GRC tools needed
Signal category
Risk

Topics and mentions

Technologies

  • TrumpRx.gov

Regions named

  • U.S.
  • United States

Extraction

Confidence
High
Relevance
85%
Sentiment
Negative
Detected
Nov 9, 2026
signal_type
sec-10q
signal_subtype
complianceBurden

Use this data

Get every 10-Q signal for Regeneron and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Regeneron this week?”

  2. Send it to your own tools

    The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/7ab86939-9115-40ab-8382-ca8f21e5f0ff returns this record as JSON. POST /v1/companies/enrich returns every signal for regeneron.com.

{
  "signal_id": "7ab86939-9115-40ab-8382-ca8f21e5f0ff",
  "signal_type": "sec-10q",
  "signal_subtype": "complianceBurden",
  "detected_at": "2026-11-09T06:24:49.509+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "detail": "Regeneron entered into agreements with the U.S. government to benchmark U.S.-wholly owned products sold to Medicaid against foreign developed countries and participate in TrumpRx.gov. These extensive drug pricing and distribution commitments will require vendors offering compliance monitoring, government pricing analytics, and direct-to-patient fulfillment solutions.",
    "metrics": {
      "timeframe": "multi_year"
    },
    "quarter": "Q1",
    "summary": "Regeneron Agrees to Most-Favored-Nation Medicaid Pricing and Direct Purchasing with U.S. Government in April 2026",
    "excerpts": "In April 2026, we announced agreements with the U.S. government (the \"U.S. Government Agreements\") pursuant to which we have agreed, among other matters, to provide certain of our products that we wholly own in the United States to the Medicaid program at or below prices benchmarked against a defined group of other developed countries (\"Most-Favored-Nation Pricing\"). We have also agreed to price certain future medicines in the United States at or below Most-Favored-Nation Pricing; to participate in a direct purchasing platform, TrumpRx.gov, that will allow eligible patients to purchase Praluent directly; and to provide our recently FDA-approved gene therapy Otarmeni™ for free in the United States.",
    "relevance": 0.85,
    "sentiment": "negative",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/872589/000087258926000016/regn-20260331.htm",
    "filing_date": "2026-04-29",
    "filing_year": 2026,
    "fiscal_year": 2026,
    "fiscal_year_end": "03/31",
    "period_end_date": "2026-03-31",
    "sales_relevance": "GRC tools needed",
    "signal_category": "risk",
    "regions_mentioned": [
      "U.S.",
      "United States"
    ],
    "technologies_mentioned": [
      "TrumpRx.gov"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.